

Supplemental Data Table S1. Baseline characteristics of the study population

Characteristic	Study population (N = 47)
Sex, N (%)	
Female	18 (38.3)
Male	29 (61.7)
Age (yr)	
Mean (SD)	65.5 (12.8)
2016 WHO classification, N (%)	
MDS-EB	10 (21.3)
MDS-EB1	3 (6.4)
MDS-EB2	7 (14.9)
AML with recurrent genetic abnormalities	17 (36.2)
AML with mutated <i>NPM1</i>	8 (17.0)
AML with biallelic mutation of <i>CEBPA</i>	3 (6.4)
AML with mutated <i>RUNX1</i>	6 (12.8)
AML with MRC	9 (19.1)
AML, NOS	10 (21.3)
Therapy-related myeloid neoplasms	1 (1.3)

Abbreviations: MDS-EB, MDS with excess blasts; MRC, myelodysplasia-related changes; NOS, not otherwise specified.